Buccal Drug Delivery Systems

Global Buccal Drug Delivery Systems Market to Reach US$5.8 Billion by 2030

The global market for Buccal Drug Delivery Systems estimated at US$4.3 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Buccal Tablets & Lozenges, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Sublingual Films & Wafers segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.1% CAGR

The Buccal Drug Delivery Systems market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Buccal Drug Delivery Systems Market – Key Trends & Drivers Summarized

What Are Buccal Drug Delivery Systems and Why Are They Important in Modern Medicine?
Buccal drug delivery systems are pharmaceutical formulations designed for administration through the buccal mucosa, the inner lining of the cheeks. This route allows for the direct absorption of drugs into the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver, which can degrade certain medications. Buccal drug delivery offers several advantages, including rapid onset of action, improved bioavailability, and ease of administration, making it ideal for patients with swallowing difficulties or those requiring fast-acting medication. These systems come in various forms, such as tablets, films, patches, sprays, and gels, designed to adhere to the mucosal surface for sustained drug release. Buccal delivery is commonly used for drugs like nitroglycerin (for angina), fentanyl (for pain management), and insulin, as well as in hormone therapies, vaccines, and treatments for systemic diseases. Its non-invasive nature and convenience make it an attractive alternative to traditional oral and injectable routes.

How Are Technological Advancements Enhancing Buccal Drug Delivery Systems?
Technological innovations have significantly advanced buccal drug delivery systems, improving drug stability, absorption rates, and patient compliance. The development of mucoadhesive polymers has enhanced the ability of formulations to adhere to the buccal mucosa, ensuring prolonged contact time and controlled drug release. Nanotechnology plays a critical role in optimizing drug delivery, with nanoparticles and liposomes improving solubility, bioavailability, and targeted delivery. Advances in permeation enhancers have facilitated the absorption of large molecules, such as peptides and proteins, which traditionally faced challenges in crossing mucosal barriers. 3D printing technology is also emerging as a tool for customizing buccal drug delivery devices, allowing precise control over dosage and release profiles. Furthermore, smart drug delivery systems with integrated sensors are being developed to monitor drug release and patient adherence in real time. These technological breakthroughs are expanding the potential applications of buccal drug delivery across a wide range of therapeutic areas.

What Are the Current Trends in the Buccal Drug Delivery Systems Market?
The buccal drug delivery market is experiencing dynamic growth driven by the increasing demand for non-invasive, patient-friendly drug administration methods. There is a growing focus on personalized medicine, with buccal systems offering customizable dosing options tailored to individual patient needs. The rise of biologics and peptide-based drugs has fueled interest in buccal delivery as an alternative to injections, particularly for chronic conditions requiring long-term treatment. Additionally, the pharmaceutical industry is exploring buccal delivery for novel therapies, including vaccines, gene therapies, and cannabinoids. The trend towards self-administration and home-based healthcare solutions has also contributed to the market’s growth, as buccal systems are easy to use without medical supervision. Regulatory agencies are supporting the development of buccal formulations through streamlined approval pathways, recognizing their potential to improve patient outcomes. Sustainability is another emerging trend, with eco-friendly packaging and biodegradable materials being incorporated into product designs to reduce environmental impact.

The Growth in the Buccal Drug Delivery Systems Market Is Driven by Several Factors…
The growth in the buccal drug delivery systems market is driven by several factors, including the increasing prevalence of chronic diseases, the demand for rapid-onset therapies, and the rising preference for non-invasive drug delivery methods. Technological advancements in formulation science, such as mucoadhesive technologies and nanocarriers, have improved the efficacy and safety of buccal products. The growing geriatric population, which often faces difficulties with traditional oral medications, has further increased demand for buccal systems. Additionally, the surge in biologics and the need for efficient delivery of large-molecule drugs have expanded the application of buccal routes in areas like oncology, endocrinology, and pain management. Regulatory support, coupled with increased investment in pharmaceutical research and development, has accelerated product innovation and market expansion. The convenience of buccal drug delivery, combined with its potential for improved patient compliance and therapeutic outcomes, positions it as a key growth area in the global pharmaceutical landscape.

SCOPE OF STUDY:

The report analyzes the Buccal Drug Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Buccal Tablets and Lozenges, Sublingual Films and Wafers, Oral Sprays); Application (Smoking Cessation Application, Pain Management Application, Angina Pectoris Application, Other Applications); End-Use (Hospitals End-Use, Ambulatory Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Adare Pharmaceuticals
• Alpex Pharma
• Aptar Pharma
• ARx, LLC
• Bayer AG
• BioDelivery Sciences International, Inc.
• Catalent, Inc.
• Cipla Limited
• Cynapsus Therapeutics Inc.
• Endo Pharmaceuticals plc
• Generex Biotechnology
• GlaxoSmithKline plc
• Haleon
• Indivior Pharmaceuticals
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.